Navigation Links
Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
Date:4/23/2009

LAIYANG, China, April 23 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) (the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has changed its name to "Jiangbo Pharmaceuticals, Inc." ("Jiangbo").

The Company received confirmation from the Department of State of the State of Florida that the Certificate of Amendment to the Company's Amended and Restated Articles of Incorporation to effect a change of its name was filed. The Board of Directors of the Company as well as the holders of a majority of the outstanding shares of the Company's voting stock approved the name change by written consent. The Company will soon receive a new CUSIP number for its common stock, after which a new ticker symbol for the Company's shares will be assigned by the OTCBB. The Company will announce its new ticker symbol and CUSIP number as soon as it receives them.

The Company's wholly owned operating subsidiary Laiyang Jiangbo Pharmaceutical Co., Ltd., a PRC company, markets the Company's products throughout China under the brand name "Jiangbo." Part of the Company's branding strategy includes using similar packaging for its products and creating a product line of drugs which are widely known by Jiangbo's brand name and logo.

"We support Jiangbo with the idea that 'We aim high, We aim wide.' It is part of our corporate culture to provide our customers with products that will help them lead happy and healthy lives. We always strive to produce the best possible quality products and ensure our reputation while we continue to grow our Company's revenues, profits and value," said Mr. Wubo Cao, Chief Executive Officer of Jiangbo.

"We changed our corporate name to Jiangbo to align the name of our public company with the name of our products. With this change, we hope that our
'/>"/>

SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
2. Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009
3. Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
4. New Directions in Angioedema: A Focus on Pathogenesis and Classification
5. Angiogenesis inhibitor improves brain tumor survival by reducing edema
6. CFO of Genesis Pharmaceuticals Gives Live Interview on Bloomberg TV Asia
7. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
8. Study sheds light on angiogenesis inhibitors, points to limitations, solutions
9. Thermogenesis Technology Products Surpass Processing of More Than One Million Units of Cord Blood Stem Cells at 10-Year Milestone
10. Genesis Successfully Defends Multi-Million Dollar Arbitration Filed by CRG and CRGP; Related Parties Withdraw Remaining Demands for Arbitration Against Genesis
11. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 411 More Children Die From Swine Flu 3A CDC 59676 111 More Children Die From Swine Flu 3A CDC 59676 211 More Children Die From Swine Flu 3A CDC 59676 3President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 1President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 2President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 3President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 4President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 5President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 6Peregrine Pharmaceuticals Announces Implementation of 1 3A5 Reverse Stock Split to Take Effect October 19 2009 59666 1Peregrine Pharmaceuticals Announces Implementation of 1 3A5 Reverse Stock Split to Take Effect October 19 2009 59666 2Peregrine Pharmaceuticals Announces Implementation of 1 3A5 Reverse Stock Split to Take Effect October 19 2009 59666 3Peregrine Pharmaceuticals Announces Implementation of 1 3A5 Reverse Stock Split to Take Effect October 19 2009 59666 4
Other Medicine Technology:Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 2Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 3Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 4Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 5Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7